Stifel analyst Paul Matteis reiterated a Buy rating on Cerevel Therapeutics (NASDAQ: CERE) following the recently announces results from the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE